Choosing the right country for a clinical trial, particularly in complex therapeutic diseases, is a difficult task due to its reliance on factors that databases and standard metrics cannot fully measure. When therapies involve advanced technologies like modified immune cells or genetic interventions, the analysis must extend beyond basic feasibility. It requires examining site capabilities for complex sample handling, investigator experience with similar treatment mechanisms, patient access to the diagnostic tests needed for screening, and regulatory familiarity. 

Traditionally, sponsors have relied on a familiar set of quantitative indicators to guide country selection. These include regulatory approval timelines, disease prevalence, patient population size, historical enrollment rates, site experience, cost per patient, and competitive trial density. These metrics remain essential and form the foundation of early feasibility planning.

But as complex therapeutic areas introduce difficulties, such as specialized equipment needs, fragmented patient populations, and advanced diagnostic requirements, these traditional approaches fall short. A few examples below point out what this looks like in practice:

• Cancer trials targeting specific mutations: A country might show high overall cancer rates, but only a fraction of patients have the precise genetic mutations needed. Even fewer can access the genetic testing required to screen them in the first place.
• CAR-T cell therapy for blood cancers: These treatments demand ultra-cold storage, specialized equipment to collect patient cells, and manufacturing coordination across continents. 
• Rare genetic disorders: When fewer than 500 people worldwide have a condition each year, patients scatter across countries. Diagnoses take years, and many regions lack genetic screening infrastructure entirely.

These examples clearly highlight the gap between what data suggests and what actually happens on the ground. And this could be accounted for, especially in complex therapeutic areas. 

This article examines why traditional country selection methods are no longer sufficient for trials in complex therapeutic diseases. It also discusses how investigators and sites provide the missing insights that metrics cannot capture, and what sponsors can do to make better-informed decisions that account for the realities. 

However, to understand why country selection for clinical trials in complex therapeutic diseases requires a fundamentally different approach, let us first examine how therapeutic complexity is reshaping the clinical trial landscape.  

How therapeutic complexity is changing trial execution

Particularly in trials involving advanced therapies and rare disease populations, the trial execution faces notable challenges. Even countries that look promising based on traditional metrics are struggling.

Recent data reveals several trends driven by therapeutic complexity:

• Molecular stratification fragmenting patient pools: Over 80% of oncology trials now face recruitment delays, largely because patient populations fragment dramatically when targeting specific biomarkers. 
• Infrastructure gaps for advanced therapies: Fewer than 200 centers globally possess the specialized facilities required for cell and gene therapies. Which requires ultra-cold storage, cleanroom manufacturing capabilities, and complex sample logistics. 
• Diagnostic access barriers: In trials requiring advanced genetic testing or molecular profiling for patient selection, 37% of sites under-enroll because local healthcare systems don’t routinely perform these tests. 
• Protocol complexity overwhelming sites: Trials in complex therapeutic areas now involve 30-40% more procedures than five years ago. Sites that performed well on simpler protocols often lack the specialized personnel or experience to manage intricate monitoring requirements.

These patterns reveal that country-level data cannot predict what actually happens at individual sites. Hence, selecting countries for clinical trials in complex therapeutic areas requires a balanced evaluation of multiple interdependent factors. Investigators can bridge this gap, as they understand how care pathways, staffing, and patient behavior function in practice.

The following table illustrates the gap between what data reveals and what the operational realities are:

Data-driven metrics	Operational realities
Disease prevalence statistics	Actual patient access through referral networks
Published regulatory timelines	Informal approval processes and local requirements
Historical site performance	Current site capacity and competing trial burden
Infrastructure availability	Staff expertise and operational readiness
Cost-per-patient estimates	True retention costs, including local barriers

In the following section, we will explore this topic in depth. We will look at the factors that influence the decision of country selection and the significance of the investigators’ experiences and knowledge in the process. 

Why investigator and site perspectives matter

The on-the-ground knowledge that investigators and sites possess can bridge the gap between what data suggests and what is feasible.  In complex therapeutic areas, their insights become even more critical. The following points explain it all:

Protocol feasibility evaluation and optimization through investigator input

Investigators identify specific misalignment sources before they impact enrolment, such as:

• Diagnostic procedures not matching local standard of care: For example, a protocol requiring fresh tissue biopsies when liquid biopsies are standard practice locally. Or demanding repeat molecular testing when prior results exist, etc.
• Prohibited medications conflicting with treatment norms: Excluding patients on corticosteroids when they’re commonly used for managing symptoms in rare inflammatory conditions.
• Exclusion criteria eliminating patients with common conditions: For example, in Duchenne muscular dystrophy trials, excluding patients with mild cardiac dysfunction that’s prevalent in the disease population.
• Requirements mismatched to local demographics: Visit schedules requiring weekly visits in countries with poor transportation infrastructure or for rare disease patients who travel hours to specialized centers.

Additional complexity-specific feasibility concerns that investigators can flag include:

• Whether the inclusion/exclusion criteria are too restrictive for the rare patient population.
• If additional stratification factors (like specific genetic mutations in basket trials) will fragment enrollment further.
• Whether comparator drugs are available, prescribable, and reimbursed locally. It is critical for rare disease trials, where the standard of care varies widely.
• If the treatment regimen conflicts with local standards of care.
• Whether the study design is achievable given local infrastructure and patient access patterns.

Also, feedback from investigators facilitates active optimization. When investigators notice discrepancies between the protocol and local practices, sponsors can determine what to do:

• Protocol changes related to issues of feasibility
• Country-specific adaptations where appropriate
• Alternative country selection in the case of poor alignment

These decisions are made during the planning phase, not after trials have been initiated. This helps avoid delays and enrollment failures, which are costly. With this strategy, scientifically valid protocols can be successfully carried out in clinical settings.

The following table presents the assumptions made for the protocol design analysis done on the data, as opposed to the assumptions found in the clinical reality:

Common protocol assumption	Investigator-identified reality
Eligible patients are readily available based on prevalence data.	Strict I/E criteria will exclude 70-80% of this population.
The visit schedule is manageable for patients	Visit burden conflicts with work/life, increasing dropout risk
The required Standard of Care is globally consistent	Local diagnostic/treatment norms conflict with protocol
Sites can easily execute all required procedures	A key procedure requires special training not available at most sites

Understanding patient access in complex therapeutic diseases through local healthcare systems

A successful trial recruitment relies on understanding patient movement from the point of diagnosis to the point of possible trial recruitment. Diagnostic pathways and trial recruitment pathways are significantly diverse across the globe, regions, and healthcare systems. Clinical trial sites that have effective investigator referral networks see a 15-25% increased rate of recruitment. This is due to the site investigators’ capacity to:

• Engage existing relationships with referring physicians
• Use diagnostic networks well
• Navigate local healthcare systems effectively

In rare disease trials or cancer studies targeting specific molecular subtypes, investigators understand:

• Which hospitals perform next-generation sequencing
• Which specialists see concentrated patient populations, 
• And how long diagnostic processes typically take. 

Investigators also recognize the cultural aspect that may influence the participation of subjects in the research. They have the ability to recognize the attitudes, expectations, and challenges within the region. 

For complex therapies like CAR-T that require multiple hospitalizations and intensive monitoring, understanding these cultural nuances becomes essential. Selecting the right country for conducting clinical trials demands such a comprehensive understanding that is unattainable through the collection of information or data-driven analysis alone.

Real site capacity assessment beyond infrastructure analysis

Sites conducting multiple studies in complex therapeutic diseases simultaneously experience patient dropout rates that are 20-30% higher. The failure to meet enrollment targets is common, too. Even when sites have robust infrastructure and skilled personnel, the disadvantage occurs because the capacity limitations outweigh the advantages of the facilities. 

However, Investigators provide realistic capacity assessments by evaluating:

• Current coordinator availability and workload
• Allocations of principal investigators by protocol
• Other trial portfolios for the same patient base

Analyzing competitive trial environments in complex therapeutic diseases

The investigators know the competitive environment of potential location areas. They look for areas where the inclusion criteria intersect and identify the workload capacity of the study coordinator for several protocols. In complex therapeutic diseases, this competitive intelligence becomes even more critical. For example,  a site might have enrolled well on a previous immunotherapy trial, but if they’re now running three competing studies for PD-L1-positive lung cancer, the historical performance becomes irrelevant. 

Therefore, with a clear understanding of how investigator insights address the limitations of data-driven approaches, sponsors can adopt strategic principles that merge both perspectives effectively. 

Recommended approaches for country selection in complex therapeutic diseases

It is a best way to merge quantitative data with investigator intelligence through several key principles for a successful country selection:

1. Combining quantitative analysis with operational intelligence
2. Engaging investigators as strategic partners
3. Validating protocols against local clinical practice
4. Pursuing strategic geographic diversification
5. Adopting a question-driven approach

Sponsors can ask strategic questions that conventional data sources can’t adequately address, and systematically answer them through investigator and site-level intelligence. The framework below illustrates how key strategic questions, often inadequately addressed through conventional data sources, can be systematically answered through investigator- and site-level intelligence.

• Can local healthcare systems identify and refer patients meeting our molecular eligibility criteria?
• Do sites have the specialized infrastructure our therapy requires, and can coordinators manage the protocol complexity?
• How does our protocol align with local treatment standards and patient population characteristics?
• What competitive trials are targeting the same patient population?
• Are there cultural or logistical barriers that will impact enrollment or retention?

At the end of the day, selecting a country for a clinical trial in complex therapeutic diseases requires aligning scientific objectives with practical execution realities. The most effective approach starts with engaging investigators early. Their insights reveal whether a country possesses the operational and cultural readiness to support the protocol. 

Conclusion

Country selection for complex therapeutic diseases trials cannot rely on data analysis alone. While metrics provide essential groundwork, investigator and site perspectives determine whether protocols can succeed locally. These frontline experts understand execution realities that databases could miss. 

Hence, early partnership with investigators leads to smarter country choices and better trial outcomes. In complex therapeutic areas where every site decision matters, this collaborative approach is essential.

---

Are you planning a clinical trial in complex therapeutic diseases like oncology or rare disease and unsure which countries or sites to choose? 

Connect with trusted investigators and clinical sites worldwide. We guide you through site feasibility to ensure you select locations that deliver results. Complete the form below, and our team will reach out to discuss your specific project needs.

---